上海医药：关于醋酸艾司利卡西平片获得美国FDA批准文号的公告

Core Viewpoint - Shanghai Pharmaceuticals has received final approval from the U.S. FDA for its abbreviated new drug application (ANDA) for Acetate Eslicarbazepine Tablets, allowing the product to be marketed in the United States [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., is the entity that received the FDA notification regarding the approval [1]